451 related articles for article (PubMed ID: 24118413)
1. Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy.
Chung BH; Choi BS; Oh EJ; Park CW; Kim JI; Moon IS; Kim YS; Yang CW
Transpl Int; 2014 Jan; 27(1):49-59. PubMed ID: 24118413
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
4. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
5. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay.
Phelan D; Mohanakumar T; Ramachandran S; Jendrisak MD
Hum Immunol; 2009 Aug; 70(8):584-8. PubMed ID: 19477211
[TBL] [Abstract][Full Text] [Related]
6. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
[TBL] [Abstract][Full Text] [Related]
7. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
9. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
[TBL] [Abstract][Full Text] [Related]
12. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
[TBL] [Abstract][Full Text] [Related]
13. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
15. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
19. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
20. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
